Top Quality FOXO4

Name:  Lynn
Wechat：  15914422644

Tel：+86  15914422644

Whatsapp: +852 6252 8290

Email：    guangsheng 5   @zgguangsheng.com

1. Core Molecular & Genomic Specifications

2. Regulation & Mechanisms of Action

2.1 Core Regulatory Pathways

• PI3K-AKT Pathway (Inhibition): Insulin/IGF-1 activates PI3K→AKT, which phosphorylates FOXO4, promoting 14-3-3 binding and cytoplasmic sequestration, blocking transcription.
• JNK Pathway (Activation): Oxidative stress/TNF-α activates JNK, phosphorylating FOXO4 (Thr447/451), driving nuclear translocation and target gene expression (e.g., MnSOD, CAT)PMC.
• SIRT1-CBP Axis: CBP-mediated acetylation inhibits activity; SIRT1 deacetylation (NAD+-dependent) restores transcriptional function.
• Ubiquitination: Monoubiquitination (oxidative stress) enhances nuclear entry; USP7 deubiquitination promotes cytoplasmic localization.

2.2 Key Target Genes & Cellular Functions

3. Biological Roles & Disease Associations

3.1 Physiological Functions

• Aging & Longevity: Promotes stress resistance and suppresses senescence; FOXO homolog daf-16 extends lifespan in C. elegans.
• Metabolic Homeostasis: Regulates hepatic gluconeogenesis, insulin signaling, and lipid metabolism.
• Tissue Protection: Antioxidant and anti-apoptotic effects in heart/muscle; preserves function under ischemia/reperfusion.
• Immune & Stem Cell Regulation: Modulates thymic function and ESC proteostasis.

3.2 Disease Links

• Cancer: Acts as a tumor suppressor (induces p27Kip1, apoptosis); loss-of-function mutations or AKT-driven inactivation in leukemia, breast, colon cancer; MLLT7 translocation linked to acute myeloid leukemia (AML)National Center for Biotechnology Information.
• Metabolic Diseases: Impaired FOXO4 activity associates with insulin resistance and type 2 diabetes; regulates hepatic glucose output.
• Osteoporosis: CBP-acetylated FOXO4 inhibits Wnt/β-catenin, reducing osteogenesis and accelerating bone loss in postmenopausal modelsNational Center for Biotechnology Information.
• Cardiovascular Disease: Protects cardiomyocytes from oxidative stress; reduced activity linked to heart failure and atherosclerosis.

4. Research Tools & Applications

4.1 Reagents & Assays

• Antibodies: Phospho-specific (p-Thr28, p-Ser258) and total FOXO4 antibodies for WB/IF/IHC.
• Expression Vectors: Wild-type (WT), constitutively active (CA: AKT-site mutants), dominant-negative (DN) constructs.
• Reporter Assays: Luciferase vectors with IREs (e.g., IGFBP1 promoter) to measure FOXO4 transcriptional activity.
• Small Molecules: Activators (metformin, rapamycin, spermidine); inhibitors (AKT agonists, CBP activators).

4.2 Research Directions

• Aging & Senescence: FOXO4-DRI peptide (disrupts FOXO4-p53 interaction) clears senescent cells in mice, improving age-related pathologies (e.g., frailty, atherosclerosis).
• Cancer Therapy: Restore FOXO4 activity via PI3K/AKT inhibitors or SIRT1 activators to induce tumor cell cycle arrest/apoptosis.
• Metabolic Disorders: Target FOXO4 to enhance insulin sensitivity and glucose control in diabetes.
• Osteoporosis: Inhibit CBP-mediated acetylation of FOXO4 to restore Wnt/β-catenin signaling and osteogenesisNational Center for Biotechnology Information.